Study ID: C38072/3082

Study Title

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Teva Identifier

C38072/3082

ClinicalTrials.gov Identifier

NCT01287039

Study Status

Completed

Trial Condition(s)

Eosinophilic Asthma

Interventions

Drug: Reslizumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

12 Years to 75 Years

Trial Duration

04/01/2011 - 03/01/2014

Phase

Phase 3

Study Type

Interventional